Navigation Links
The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus' Solicitation Efforts
Date:5/7/2009

you should have received The Quigley Corporation proxy statement for our 2009 Annual Meeting, along with a WHITE proxy card. We urge all stockholders to protect your investment and vote the WHITE card immediately. Disregard any proxy materials you may receive from dissident stockholder Ted Karkus, who is seeking to replace your Company's entire incumbent Board of Directors.

MANAGEMENT'S STRATEGIC PLAN HAS BEEN CAREFULLY DEVELOPED AND

EXECUTED - AND IT'S WORKING!

The Quigley Corporation, under the guidance of the incumbent Board and management, has a carefully developed long term strategic plan to increase stockholder value by investing a share of the profits from its successful, market leading OTC homeopathic cold remedy to self-fund research and development of naturally-derived medicinal compounds for which there is enormous market potential.

On April 30, 2009 the Company issued a major announcement regarding noteworthy results from Phase II testing of its QR-333 compound to treat Diabetic Peripheral Neuropathy:

POSITIVE FINDING FOR QR-333 COMPOUND TO TREAT DIABETIC PERIPHERAL

NEUROPATHY EXPANDS POTENTIAL

Diabetic Peripheral Neuropathy is a common complication of diabetes associated with nerve damage in the feet and hands. According to the American Diabetes Association, over 20 million people in the U.S. have diabetes, which grew 13.5% from 2005 to 2007. According to Datamonitor, the market for drugs to treat this problem is $2.8 billion today and is expected to grow to $6.0 billion by 2017. The clinical study of the QR-333 compound showed a sizeable increase in nerve conduction speed and strength of sensory nerve signals, suggesting that the compound may have the potential to both reverse and stop nerve damage. Your management team is on track to explore multiple next step options for the compound, which i
'/>"/>

SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. The Quigley Corporation Reports First Quarter 2009 Results
2. Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
3. The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future
4. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
5. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
6. The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director
7. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
8. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
9. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
10. Service Corporation International Announces First Quarter 2009 Financial Results
11. Providence Service Corporation Announces Record Revenues and Earnings in the First Quarter of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... “Have you recently been involved in an auto accident?” asks ... the greater Seattle area. “Are you still feeling the physical ... . , In a recently released article, Dax Jones asks ... use to see if they may qualify for a personal ... will allow an individual to receive medical treatment for their ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin ... Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast ... major drivers,restraints, challenges, opportunities, current market trends,and strategies ... the estimates and forecasts of the revenue and ...
(Date:8/20/2014)... 20, 2014 Mixberry Media announced today ... websites and create a new source of revenue. , ... by listening to a narration of their favorite news ... and languages. Users can now multitask: read/write email, ... while consuming content. , Mixberry Media’s service ...
(Date:8/20/2014)... Astoria, New York (PRWEB) August 20, 2014 ... to the Global Bureau of Disease, low back pain is ... of the most common reasons for missed work. Americans spend ... of this pain. , Most cases of back pain are ... a mechanical (non-organic) origin. , For example, Pete, a busy ...
(Date:8/19/2014)... 20, 2014 Midtown Dentistry in Houston, Texas, ... office. All patients with cavities, or with old fillings ... fillings that can safely repair and restore teeth. , From ... latest materials, all of which are completely amalgam free. Even ... use by the FDA for adults and children over the ...
Breaking Medicine News(10 mins):Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Physical Therapists Learn to Relieve Low Back Pain 2Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2
... , , WASHINGTON , Jan. 13 ... and Bruce A. Mrusek , a resident of Maineville, Ohio , ... Judge Michael R. Barrett in Cincinnati , the Justice Department ... both dentists, wer e i n d ...
... say , WEDNESDAY, Jan. 13 (HealthDay News) -- ... tendon doesn,t appear to be effective, a new study ... plasma (PRP) injections are no better than placebo in ... active. , The study included 54 patients, aged 18 ...
... And rates among boys aged 6-19 still climbing, government study ... news in the war on weight: Obesity in the United ... studies show. , But the rates of obesity remain high, ... category. And, rates of obesity among already heavy 6- to ...
... researchers have found that six essential oils from thyme, ... COX-2 enzyme, in a manner similar to resveratrol, the ... They also identified that the chemical carvacrol was primarily ... appearing in the January issue of Journal of ...
... ... to provide fully integrated topical clinical phase 1 study services for trials in healthy ... , ... January 13, 2010 -- Synomics Pharma and BioScience Laboratories, Inc. announced a formal partnership ...
... January 21st ... Understand the Latest Developments in VoIP Fax Capabilities, , ... Tigard, Oregon (Vocus) January 13, 2010 -- FaxBack , the ... the Miami Beach Convention Center. , , , , ,At the show, FaxBack (booth ...
Cached Medicine News:Health News:Two Cincinnati Dentists Plead Guilty to Conspiracy, Tax Evasion on Eve of Trial 2Health News: U.S. Obesity Rates Leveling Off, But Still High 2Health News: U.S. Obesity Rates Leveling Off, But Still High 3Health News:Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services 2Health News:Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services 3Health News:FaxBack Participates in VoIP Fax Discussion at ITEXPO 2Health News:FaxBack Participates in VoIP Fax Discussion at ITEXPO 3
(Date:8/19/2014)...  Northwest Biotherapeutics (NASDAQ: NWBO ) (NW ... for solid tumor cancers, announced today that the $17.5 ... 2014, has closed.  The three-year notes have a 5% ... of common stock.  The investors also have an option, ... additional 30% of these notes on the same terms. ...
(Date:8/19/2014)... Aug. 19, 2014  Tokyo-based Atonarp Inc. announced ... round led by Walden Riverwood Ventures with participation ... of Atonarp,s Smart Spectrometer technology platform, which will ... has targeted the oil & gas and healthcare ... are excited to partner with Atonarp in pursuing ...
(Date:8/19/2014)... 19, 2014 Avizia, Inc., a leading provider ... closed an equity financing round led by NextGen Angels ... new funding will be used to continue to fuel ... Avizia welcomes Edward Kennedy , CEO and president ... joins Leonard Kurtzman , CFO of newBrandAnalytics, who ...
Breaking Medicine Technology:NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures 2Avizia Closes Funding Round 2
ENDO STITCH™ Single Use Loading Units....
The ENDO CLOSE™ trocar site closure device has application in laparoscopic procedures for approximation of tissues and percutaneous suturing for closing incision sites....
This ENDOLOOP suture has a suture type - 0 PDSII and a 1.5 inch diameter....
... ligature inserted into a plastic tube. The plastic tube ... other. The suture protrudes from the narrow end and ... which becomes secure after the device is activated. The ... scored end of the plastic tube. The scored end ...
Medicine Products: